Conference abstractPublished 8 Sep 2014
Production and analysis of biosimilars and follow on biologics in developing countries
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Although management of chronic diseases has been a major challenge for healthcare systems in developed and developing countries, biopharmaceuticals have been successful in treating many life threatening conditions. However, the high cost of these agents restricts their availability to countries where patients and/or healthcare systems are able to afford them. Licensing these biopharmaceuticals as biosimilars after expiration of their patents might increase access to these medicines at an affordable price in developing countries. South Egypt Drug Industries Company (SEDICO) is an Egyptian pharmaceutical company that got an opportunity to manufacture some of these drugs. SEDICO biotech products, such as Insulin, erythropoietin, streptokinase, angiokinase, follicle-stimulating hormone (FSH), aprotinin, filgrastim (G-CSF) and somatropin, have been available in the Egyptian market for more than seven years. In this article, biosimilars which were tested and examined over years in SEDICO was chosen as a representative example of biotech products in south countries. The results confirmed that most of SEDICO biosimilar products can compete with the originator biologics in the Egyptian market with high quality challenge and lower cost opportunity.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Wael Ebied”
